Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Sponsor
Alexandria University
Study ID
NCT06835322
Phase
PHASE2
Status
Completed

Conditions

  • Glomerulonephritis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Finerenone — DRUG
    50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 9 months.
  • Placebo — DRUG
    50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 9 months.

Study Details

This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.

Key Dates

Start date
Apr 1, 2025
Status verified
May 2026
Primary completion
Mar 1, 2026
Completion
Apr 1, 2026

Study Design

Enrollment
100 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: interventional
    50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 9 months.
  • Placebo Comparator: placebo
    50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 9 months.

Primary Outcome Measure

- Change in kidney function [ Time Frame: 9 months ]

Related Studies